Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs 5,539

Quick answer

Oncology: NovaPharmaNews indexes 5,539 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Pipeline programs

Page 24 of 116

  1. UC-GIG-2408

    Ningbo Cancer Hospital

    Patients ≥75 years old with cT3/T4 rectal adenocarcinoma eligible to radiotherapy, FOLFOX chemotherapy and total mesorectal excision (TME) surgery

    phase 3 small molecule active

    1 trial

  2. UC-GIG-2410

    Ningbo Cancer Hospital

    Stage III colorectal cancer

    phase 3 small molecule active

    1 trial

  3. UC-GTG-2301

    Ningbo Cancer Hospital

    Novo metastatic hormone-sensitive prostate cancer (mHSPC) patients having a serum PSA level of ≥ 0.2 ng/mL at 6 to 8 months after systemic treatment initiation for mHSPC (i.e. poor responders) in the absence of evidence of cancer progression (including a rising PSA level)

    phase 3 small molecule active

    1 trial

  4. UC-GTG-2306

    Ningbo Cancer Hospital

    Castrate-resistant prostate cancer with oligometastases on functional imaging (PSMA or choline/fluciclovine-positron-emission tomography).

    phase 3 small molecule active

    1 trial

  5. UC-IMM-2101

    Ningbo Cancer Hospital

    Only patients with oncologic locally advanced or metastatic tumour (lung cancer, renal cell cancer (except IMDC favorable-risk treated Tyrosine Kinase Inhibitor [TKI] / immunotherapy [IO] combination), head and neck cancer, urothelial carcinoma, triple negative breast cancer, Merkel cancer, melanoma, hepatocellular carcinoma, colorectal carcinoma with microsatellite instability [MSI], esophageal squamous cell carcinoma, endometrial carcinoma, or cervical cancer, gastric/gastro-esophageal junction/esophageal adenocarcinoma, basal cell carcinoma or squamous skin carcinoma) in partial or complete response (except for melanoma, only patients in partial response) after 6 months of standard IO treatment (monotherapy or previously in combination with other immunotherapy (ipilimumab) or chemotherapy or continuous combination with pemetrexed or bevacizumab or TKI).

    phase 3 small molecule active

    1 trial

  6. UGN-102 (Mitomycin)

    Lacuna Pharma Pty Ltd

    Non-Muscle Invasive Bladder Cancer

    phase 3 small molecule active

    1 trial

  7. UGN-103 (Mitomycin)

    Lacuna Pharma Pty Ltd

    Nonmuscle Invasive Bladder Cancer

    phase 3 small molecule active

    1 trial

  8. UGN-104

    Lacuna Pharma Pty Ltd

    Low-grade Upper Tract Urothelial Cancer

    phase 3 small molecule active

    1 trial

  9. URONCOR 06-24

    The George Institute

    Prostate Cancer

    phase 3 small molecule active

    1 trial

  10. Ublituximab

    TG THERAPEUTICS, INC.

    Chronic Lymphocytic Leukemia

    phase 3 small molecule completed

    5 trials

  11. Ublituximab

    TG THERAPEUTICS, INC.

    Diffuse Large B-Cell Lymphoma

    phase 3 mab terminated

    1 trial

  12. Unesbulin

    PTC Therapeutics International Limited

    Leiomyosarcoma

    phase 3 small molecule terminated

    1 trial

  13. Unesbulin

    PTC THERAPEUTICS, INC.

    Leiomyosarcoma

    phase 3 small molecule terminated

    2 trials

  14. V503-021

    Merck Sharp and Dohme

    ​9vHPV vaccine is indicated in females ≥ 9 years of age in the prevention of cervical, vulvar, vaginal, and anal cancer; precancerous or dysplastic lesions; and persistent infections caused by Human Papillomavirus (HPV) types 16, 18, 31, 33, 45, 52, and 58, and genital warts (condyloma acuminata) caused by HPV types 6 and 11.​

    phase 3 small molecule active

    1 trial

  15. V940-002

    Merck Sharp and Dohme

    Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  16. V940-007

    Merck Sharp and Dohme

    The participants must have a histologically confirmed diagnosis of resectable cSCC as the primary site of malignancy (metastatic skin involvement from another primary cancer or from an unknown primary cancer is not permitted).

    phase 3 small molecule active

    1 trial

  17. V940-009

    Merck Sharp and Dohme

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  18. VATS

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Lung Cancer

    phase 3 other active

    1 trial

  19. VERDYE 5 mg/ml poeder voor oplossing voor injectie

    Disc Medicine

    Histologically confirmed solid malignancy (e.g., head and neck, gastrointestinal, hepatobiliary, breast, genitourinary, sarcoma)

    phase 3 small molecule active

    1 trial

  20. VS-6766-301

    Vera Therapeutics

    Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

    phase 3 small molecule active

    1 trial

  21. Vandetanib

    Sanofi Pasteur

    Locally Advanced or Metastatic Medullary Thyroid Cancer

    phase 3 small molecule completed

    1 trial

  22. Vandetanib

    Sanofi Pasteur

    Non Small Cell Lung Cancer

    phase 3 small molecule completed

    1 trial

  23. Vectibix 20 mg/ml concentrate for solution for infusion

    Fondazione Telethon ETS

    Unresectable left sided RAS/B-RAF wild-type metastatic colorectal cancer

    phase 3 small molecule active

    1 trial

  24. Vemurafenib

    Hoffmann-La Roche

    Malignant Melanoma

    phase 3 small molecule completed

    2 trials

  25. Venetoclax

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia

    phase 3 small molecule active

    1 trial

  26. Venetoclax

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Lymphoblastic Leukemia

    phase 3 small molecule active

    1 trial

  27. Venetoclax

    AbbVie

    Chronic Lymphocytic Leukemia

    phase 3 small molecule active

    1 trial

  28. Venetoclax 400

    United Therapeutics Europe Ltd

    Acute Myeloid Leukemia

    phase 3 small molecule active

    1 trial

  29. Ventoclax

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    AML (Acute Myelogenous Leukemia)

    phase 3 small molecule active

    1 trial

  30. Verum acupuncture

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Colorectal Cancer

    phase 3 other active

    1 trial

  31. Vincristine Sulfate Liposome

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Adult Acute Lymphoblastic Leukemia

    phase 3 small molecule active

    1 trial

  32. Vinflunine

    Bristol-Myers Squibb

    Stomach Cancer

    phase 3 small molecule terminated

    1 trial

  33. Virulizin®

    Aptose Biosciences

    Pancreatic Cancer

    phase 3 small molecule completed

    1 trial

  34. Volrustomig

    Arcus Biosciences

    Advanced Clear Cell Renal Cell Carcinoma

    phase 3 small molecule active

    1 trial

  35. WO29637

    Hoffmann-La Roche

    Renal Cell Carcinoma

    phase 3 small molecule completed

    1 trial

  36. WO41535

    Hoffmann-La Roche

    High-risk hepatocellular carcinoma (HCC)

    phase 3 small molecule active

    1 trial

  37. WO41554

    Hoffmann-La Roche

    HR+/HER2-Negative Locally Advanced or Metastatic Breast cancer with PIK3CA mutation

    phase 3 small molecule active

    1 trial

  38. WO41994

    Hoffmann-La Roche

    Renal cell carcinoma (RCC)

    phase 3 small molecule active

    1 trial

  39. WO42633

    Hoffmann-La Roche

    Early human epidermal growth factor receptor 2 (HER2) positive breast cancer

    phase 3 small molecule active

    1 trial

  40. WO45654

    Hoffmann-La Roche

    Endocrine-Sensitive phosphatidylinositol 3-kinase (PIK3CA)-Mutated, Hormone Receptor-Positive, human epidermal growth factor receptor 2- (HER2-) negative advanced breast cancer

    phase 3 small molecule active

    1 trial

  41. WO46069

    Hoffmann-La Roche

    Pretreated Unresectable Locally Advanced or Metastatic human epidermal growth factor receptor 2 (HER2)-Positive Breast Cancer, with or without Central Nervous System (CNS) Metastases

    phase 3 small molecule active

    1 trial

  42. XPORT-DLBCL-30

    Karyopharm Therapeutics Inc

    Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL)

    phase 3 small molecule active

    1 trial

  43. Xevinapant (Debio 1143)

    Serono Europe Limited

    Squamous Cell Carcinoma of the Head and Neck

    phase 3 small molecule terminated

    1 trial

  44. Xofigo 1100 kBq/mL solution for injection

    Ningbo Cancer Hospital

    metastatic Castration-Resistant Prostate Cancer (mCRPC)

    phase 3 small molecule active

    1 trial

  45. Xtandi - soft capsules for Castration resistant prostate c…

    Ningbo Cancer Hospital

    Castration resistant prostate cancer patients metastatic to bone.

    phase 3 small molecule active

    1 trial

  46. YO29232

    Hoffmann-La Roche

    Carcinoma, Non-Small-Cell Lung

    phase 3 small molecule completed

    1 trial

  47. YO42137

    Hoffmann-La Roche

    Unresectable Esophageal Squamous Cell Carcinoma

    phase 3 small molecule active

    1 trial

  48. YiQiFang

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Cancer

    phase 3 small molecule completed

    2 trials

Frequently asked questions

How many oncology pipeline programs are tracked?

5,539 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.